GlassScriptPhysician profile
Meagan Lemaster
NPI 1851639017
$3,970.64
in general payments reported to CMS, 2019-2025
34 companies · $1,586 in 2025
The $1,586 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $248 · 2022: $129 · 2023: $519 · 2024: $1,489 · 2025: $1,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,415 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,415.44 |
| Education | $178.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $815.37 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $548.00 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $325.04 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $285.24 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Celltrion USA INC. | $193.08 | 2024-2025 | Zymfentra, Vegzelma |
| Qol Medical, LLC | $180.47 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.94 | 2024-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $142.37 | 2021 | |
| Novo Nordisk INC | $142.15 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $132.43 | 2023-2025 | Dupixent |
| Pfizer INC. | $131.60 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $127.54 | 2023-2024 | Rebyota |
| Ironwood Pharmaceuticals, INC | $99.46 | 2024-2025 | |
| Celgene Corporation | $70.29 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $59.07 | 2023-2025 | Ocaliva |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $55.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Cvrx, INC. | $44.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.13 | 2022-2023 | Cyltezo |
| Lilly USA, LLC | $42.34 | 2024-2025 | Omvoh |
| Tersera Therapeutics LLC | $36.94 | 2023 | Xermelo |
| Gilead Sciences, INC. | $35.78 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $33.56 | 2021 | |
| Phathom Pharmaceuticals, INC. | $31.59 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $29.45 | 2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $25.67 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $22.90 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.39 | 2025 | Iqirvo |
| Philips North America LLC | $19.57 | 2022 | |
| Sandoz INC. | $19.39 | 2025 | Hyrimoz |
| E.R. Squibb & Sons, L.L.C. | $19.00 | 2024 | Zeposia |
| Amarin Pharma, INC. | $15.93 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.44 | 2021 | |
| Amgen INC. | $15.16 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagan Lemaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.